Table 4 Comparison of clinical parameters between JAK2-V617F mutant and wild type in three groups of patients
Index | PMF | P | PV | P | ET | P | |||
|---|---|---|---|---|---|---|---|---|---|
M※(n = 15) | W*(n = 9) | M(n = 73) | W(n = 7) | M(n = 47) | W(n = 21) | ||||
Media age(y) | 69(42–78) | 58(47–70) | 0.122 | 58(22–78) | 49(21–74) | 0.821 | 59(28–81) | 58(18–85) | 0.532 |
Sex | |||||||||
Male | 8 | 9 | 0.027* | 42 | 6 | 0.236 | 23 | 12 | 0.605 |
Female | 7 | 0 | 30 | 1 | 24 | 9 | |||
WBC(109/L) | 7.5(2.7–23.1) | 20.7(1.3–51.8) | 0.497 | 12.6(4.3–50.3) | 6.8(4.4–12.7) | 0.006* | 12.5(6–61) | 8(5.3–26) | 0.001* |
Hb(g/L) | 90.7 ± 29.1 | 87.1 ± 46.0 | 0.303 | 193.7 ± 19.8 | 207.4 ± 29.6 | 0.089 | 144.1 ± 24.3 | 121 ± 25.6 | 0.001* |
PLT(109/L) | 147(62–617) | 192(1–806) | 0.61 | 404(93–1328) | 217(93–305) | 0.001* | 813.5(538–2240) | 985(416–2243) | 0.037* |
Splenomegaly | 15 | 9 | / | 55 | 3 | 0.045* | 20 | 3 | 0.023* |
Thrombosis | 1 | 1 | 0.62 | 12 | 1 | 0.859 | 9 | 3 | 0.742 |
Bone fibrosis | 2 | 0 | 0.657 | 2 | 1 | 0.676 | |||
APTT extension | 9 | 7 | 0.332 | 58 | 5 | 0.636 | 28 | 4 | 0.002* |
PT extension | 4 | 2 | 0.601 | 25 | 3 | 0.691 | 4 | 0 | 0.168 |
Abnormal FIB | 10 | 4 | 0.262 | 14 | 3 | 0.161 | 10 | 4 | 0.273 |
High D-Di | 9 | 6 | 0.547 | 20 | 2 | 0.625 | 15 | 9 | 0.383 |
High LDH | 15 | 9 | / | 50 | 6 | 0.668 | 25 | 14 | 0.299 |
Karyotype analysis | |||||||||
Normal | 12 | 6 | 0.499 | 68 | 7 | 0.685 | 45 | 21 | 0.475 |
Abnormal | 4 | 3 | 4 | 0 | 2 | 0 | |||